Quince Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $28.6M
- Price
- $28.10
- % Change (Daily % change from the live per-ticker quote feed.)
- -3.77%
- Volume
- 22.1K
About
Quince Therapeutics, Inc. (QNCX) operates as a biopharmaceutical firm dedicated to developing targeted treatments for debilitating and rare diseases. A cornerstone of their innovation is an extensive bone-targeting drug delivery platform, engineered to accurately transport diverse therapeutic agents, such as small molecules, peptides, and large molecules, directly to affected bone areas like fractures and disease sites. Leading their pipeline is NOV004, an anabolic peptide meticulously designed to pinpoint and accumulate its therapeutic action precisely at bone fracture locations. The company, previously known as Cortexyme, Inc., officially rebranded as Quince Therapeutics, Inc. in August 2022. Established in 2012, Quince Therapeutics is headquartered in South San Francisco, California.
Quick stats
Shares outstanding1.0M
Computed float987.7K
Float / shares97.1%
Cash runway (months)25
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001662774
Websitehttps://www.quincetx.com
AI Summary
AI-generated1/9
minorneutralother
Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on September 28, 2026
Quince Therapeutics will host a virtual key opinion leader event on Monday, September 28, 2026, from 12:30-2:00 PM ET, focused on the current treatment landscape for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and bronchiolitis obliterans syndrome (BOS).
The event features PH-ILD experts Aaron B. Waxman (Brigham and Women's Hospital) and Paul Yu (Massachusetts General Hospital) plus BOS expert Steven Hays (UCSF Health), and will review LAM-001, the company's proprietary once-daily inhaled DPI formulation of rapamycin, an mTOR inhibitor in Phase 2 development.
No new clinical data is being announced; LAM-001's fully enrolled Phase 2 BOS trial is expected to report in Q1 2027, the Phase 2b PH-ILD trial in Q1 2028, and a Phase 2 study in sarcoidosis-associated pulmonary hypertension is planned to begin in late 2026.
The release functions as an investor-education touchpoint ahead of those readouts, framing mTOR inhibition as a potentially disease-modifying mechanism across an estimated 200,000 PH-ILD patients in the U.S. and Europe.
Red flags
- No new clinical data in this release; next readouts are distant (BOS Phase 2 data Q1 2027, PH-ILD Phase 2b data Q1 2028)
- Forward-looking statements note reliance on anticipated cash runway to fund clinical development, but no runway figure is disclosed